Merck KGaA (MRK) Stock Price, News & Analysis

Company Overview

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Key Stats

• Today's Range: €126.35 to €129.40
• 50-Day Range: €126.85 to €151.50
• 52-Week Range: €134.30 to €177.00
• Volume: 335,310 shs
• Average Volume: N/A
• Market Capitalization: $56.38 billion
• P/E Ratio: 20.80
• Dividend Yield: 1.74%
• Price Target: N/A
• Consensus Rating: N/A

MRK Stock Analysis - Frequently Asked Questions

How have MRK shares performed this year?

Merck KGaA's stock was trading at €139.90 at the beginning of 2025. Since then, MRK stock has decreased by 9.5% and is now trading at €126.60.
View the best growth stocks for 2025 here.

What other stocks do shareholders of Merck KGaA own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Merck KGaA investors own include Intel (INTC), Coca-Cola (KO), Exxon Mobil (XOM), AbbVie (ABBV), Cisco Systems (CSCO), Chevron (CVX) and Alphabet (GOOG).

Industry, Sector and Symbol

• Stock Exchange: ETR
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: ETR:MRK
• CIK: N/A
• Web: www.merckgroup.com
• Phone: 49 6151 72 0
• Fax: N/A
• Employees: 69,000
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): €6.09
• Trailing P/E Ratio: 20.80
• Forward P/E Ratio: 12.75
• P/E Growth: 2.37
• Net Income: $2.76 billion
• Net Margins: 12.86%
• Pretax Margin: N/A
• Return on Equity: 9.67%
• Return on Assets: 4.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.33
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $21.46 billion
• Price / Sales: 2.63
• Cash Flow: €3.15 per share
• Price / Cash Flow: 40.17
• Book Value: €65.28 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 445,330,791
• Free Float: N/A
• Market Cap: $56.38 billion
• Optionable: Not Optionable
• Beta: 0.71